TNF and autoimmune disease: Inhibition of TNF-α activity with, for example, monoclonal antibodies as well as a receptor-immunoglobulin fusion protein has been considered an important strategy for improving clinical outcomes in patients with unresolved inflammation and associated autoimmune disorders, such as rheumatoid arthritis [61,62,63,64,65,66].